Sylvie Labrecque

TL;DR: Both p53Arg and p53Pro are morphologically wild type and do not differ in their ability to bind to DNA in a sequence-specific manner, however, there are a number of differences between the p53 variants in their abilities to bind components of the transcriptional machinery, to activate transcription, to induce apoptosis, and to repress the transformation of primary cells.

TL;DR: The anti-p53 response from cancer patients against the native and denatured state of mutant and wild type p53 is examined and it is demonstrated that the anti- p53 sera recognize both wild type and mutant p53 conformational and denaturation resistant epitopes.

TL;DR: The impact of inter‐laboratory variation in p53 genotyping on the validity of the proposed association between codon‐72 p53 polymorphism and risk of human papillomavirus (HPV)‐induced cervical cancer is assessed.

TL;DR: Inhibition of p53 with human papillomavirus E6 resulted in higher expression of heterologous transfected genes in vitro and more efficient DNA-vaccination in vivo, which has important implications for DNA vaccination against leishmaniasis and potentially against other infectious diseases.

TL;DR: A p53-responsive green fluorescent protein reporter strategy is developed to enable the identification of live cells containing p53 transcriptional transactivation activity through GFP fluorescence, which will have wide application for both in vitro and in vivo studies of the p53 tumor suppressor protein.